A patient with newly diagnosed Stage IIB malignant melanoma has been found to have a 2 cm nodule in the right lung and several enlarged lymph nodes in the axillary region. The patient's laboratory results show an elevated LDH level and mild anemia. Which nursing intervention is most appropriate to address the patient's current clinical condition?

C) Collaborate with the oncology team to discuss potential systemic therapy options.

A) Administer supplemental oxygen to alleviate potential respiratory distress.

B) Educate the patient on the importance of hydration to prevent renal complications.

C) Collaborate with the oncology team to discuss potential systemic therapy options.

D) Encourage the patient to increase dietary iron intake to address anemia.

A patient with a confirmed diagnosis of Stage IIB malignant melanoma is scheduled for a PET scan to evaluate potential metastasis. The nurse is responsible for educating the patient about this procedure. Which of the following statements made by the nurse is most appropriate to explain the purpose of the PET scan in the context of the patient's condition?

B) 'The PET scan will help evaluate the metabolic activity of tissues throughout your body to check for any spread of melanoma.'

A) 'The PET scan will help us confirm the presence of melanoma by showing the exact location of the primary tumor.'

B) 'The PET scan will help evaluate the metabolic activity of tissues throughout your body to check for any spread of melanoma.'

C) 'The PET scan is used to measure the thickness of your melanoma and determine the stage of your cancer.'

D) 'The PET scan will be used to assess the function of your liver and kidneys to ensure they are not affected by the cancer.'

A patient undergoing treatment with immune checkpoint inhibitors presents with shortness of breath, a persistent dry cough, and a right-sided pleural effusion. Which nursing intervention should be prioritized to address the patient's immediate needs?

A) Administer supplemental oxygen to improve oxygenation

B) Prepare the patient for thoracentesis to relieve pleural effusion

C) Educate the patient about potential side effects of immune therapy

D) Monitor the patient's hemoglobin levels to assess anemia

A patient undergoing treatment with immune checkpoint inhibitors presents with increased shortness of breath, a persistent dry cough, and decreased oxygen saturation. A chest CT shows increased size of a right lung nodule and a moderate right-sided pleural effusion. What is the nurse's priority intervention to address this patient's respiratory symptoms?

C) Prepare the patient for thoracentesis to relieve pleural effusion.

A) Administer supplemental oxygen to maintain saturation above 94%.

B) Encourage the patient to perform deep breathing exercises.

C) Prepare the patient for thoracentesis to relieve pleural effusion.

D) Increase the dose of the patient's bronchodilator medication.

A patient with metastatic melanoma who recently began vemurafenib therapy presents with bilateral lower extremity edema and elevated serum creatinine levels. As a nurse, what is the most appropriate initial action?

C) Notify the healthcare provider of the potential vemurafenib side effects.

A) Increase the patient's fluid intake to promote renal function.

B) Elevate the patient's legs and monitor for further edema.

C) Notify the healthcare provider of the potential vemurafenib side effects.

D) Administer a diuretic as per standing orders to reduce edema.

A patient with metastatic melanoma and a BRAF V600E mutation is receiving vemurafenib and reports new onset bilateral lower extremity edema and increased serum creatinine. Which is the most appropriate initial nursing intervention to address these symptoms?

B) Elevate the patient's legs and assess for additional signs of fluid overload.

A) Advise the patient to increase fluid intake to improve renal perfusion.

B) Elevate the patient's legs and assess for additional signs of fluid overload.

C) Notify the healthcare provider about the potential nephrotoxic effects of vemurafenib.

D) Encourage the patient to continue current medications and monitor symptoms for a week.

A patient receiving vemurafenib and ongoing immunotherapy presents with bilateral lower extremity edema and renal impairment. Which nursing intervention is most appropriate to prioritize in addressing the patient's fluid overload while considering their renal status?

C) Administer prescribed furosemide and monitor electrolyte levels closely.

A) Encourage increased oral fluid intake to promote renal perfusion.

B) Initiate a high-protein diet to manage proteinuria.

C) Administer prescribed furosemide and monitor electrolyte levels closely.

D) Position the patient in Trendelenburg to reduce edema.

A patient receiving treatment with vemurafenib presents with bilateral lower extremity edema, increased serum creatinine, and mild proteinuria. Which nursing intervention is most appropriate to prioritize in this situation?

B) Monitor the patient's electrolyte levels closely during diuretic therapy.

A) Encourage the patient to increase fluid intake to promote renal clearance.

B) Monitor the patient's electrolyte levels closely during diuretic therapy.

C) Advise the patient to continue all current medications without adjustment.

D) Initiate a high-protein diet to compensate for protein loss.

A patient with a history of melanoma is experiencing worsening renal function and mild ascites while on diuretic therapy. Which nursing intervention is most appropriate to address the patient's current symptoms and prevent further complications?

B) Educate the patient on the importance of adhering to a low-sodium diet to manage ascites.

A) Encourage the patient to increase fluid intake to flush out excess electrolytes.

B) Educate the patient on the importance of adhering to a low-sodium diet to manage ascites.

C) Advise the patient to decrease physical activity to reduce fatigue and shortness of breath.

D) Suggest the patient take over-the-counter potassium supplements to address potential electrolyte imbalances.

A patient undergoing diuretic therapy for edema related to renal impairment presents with increased fatigue, mild shortness of breath upon exertion, and worsening abdominal distention. Lab results indicate a serum creatinine level of 2.2 mg/dL and a sodium level of 132 mEq/L. Which nursing intervention is most appropriate to address the fluid and electrolyte imbalances while considering the patient's overall health condition?

D) Collaborate with the healthcare team to adjust diuretic therapy and monitor renal function and electrolyte levels.

A) Increase diuretic dosage to manage worsening abdominal distention.

B) Advise the patient to significantly reduce fluid intake to prevent further edema.

C) Encourage the patient to consume a high-sodium diet to correct hyponatremia.

D) Collaborate with the healthcare team to adjust diuretic therapy and monitor renal function and electrolyte levels.

melanoma - Nursing Case Study

Pathophysiology

• Primary mechanism: Melanoma arises from the malignant transformation of melanocytes, often initiated by DNA damage due to UV radiation. This damage leads to mutations in genes such as BRAF and NRAS, driving uncontrolled cell proliferation.

• Secondary mechanism: The evasion of immune surveillance is crucial, where tumor cells downregulate antigen presentation and secrete immunosuppressive factors, allowing unchecked growth and potential metastasis.

• Key complication: Metastasis is a critical concern, as melanoma cells invade nearby tissues and spread through lymphatic and vascular systems, commonly reaching organs like the lungs and brain, complicating treatment and prognosis.

Patient Profile

Demographics:

55-year-old male, outdoor construction worker

History:

• Key past medical history: Hypertension, basal cell carcinoma (surgically removed 5 years ago)

• Current medications: Lisinopril 10 mg daily, Aspirin 81 mg daily

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing size and changing color of a mole on the upper back

• Key symptoms: Itching and occasional bleeding of the mole, fatigue, unintended weight loss

• Vital signs: Blood pressure 150/95 mmHg, heart rate 105 bpm, respiratory rate 22 breaths per minute, temperature 37.8°C (100°F)

Section 1

New Diagnostic Results:

Following the initial assessment, the patient underwent a biopsy of the suspicious mole, which confirmed a diagnosis of malignant melanoma. The pathology report indicated a Breslow thickness of 3.5 mm and the presence of ulceration, classifying it as a Stage IIB melanoma. Additional imaging studies, including a CT scan of the chest and abdomen, revealed concerning findings: a 2 cm nodule in the right lung and several enlarged lymph nodes in the axillary region. These findings suggest possible metastasis, prompting further investigation to determine the extent of the disease.

Laboratory tests showed an elevated lactate dehydrogenase (LDH) level, which can be an indicator of tumor burden and metastatic activity. The patient's complete blood count revealed mild anemia, with a hemoglobin level of 11.5 g/dL, possibly contributing to his fatigue. Liver and renal function tests remained within normal limits, although close monitoring is warranted given the potential for systemic spread.

These diagnostic results underscore the need for a multidisciplinary approach to care, including oncology, surgical, and palliative care consultations. The patient's case is discussed in a tumor board meeting, where the consensus is to proceed with a PET scan to further evaluate metastatic spread and consider the initiation of systemic therapy, such as immune checkpoint inhibitors, to manage the disease. The healthcare team also prioritizes addressing the patient's symptomatic concerns, such as pain management and nutritional support, to optimize his overall quality of life as he navigates this complex diagnosis.

Section 2

New Complications:

A few weeks after the tumor board meeting and the initiation of systemic therapy with immune checkpoint inhibitors, the patient returns for a follow-up appointment with new symptoms. He reports increasing shortness of breath, especially with exertion, and a persistent dry cough. Upon examination, the nurse notes that his oxygen saturation is slightly decreased at 92% on room air, compared to 96% at the last visit. Lung auscultation reveals diminished breath sounds on the right side, raising concerns about possible pleural effusion or progression of the pulmonary nodule.

A repeat chest CT scan reveals an increase in size of the previously identified right lung nodule, now measuring 3 cm, and the presence of a moderate right-sided pleural effusion. The enlarged axillary lymph nodes have also increased in size, suggesting further metastatic spread. The patient's lab work shows a further rise in LDH levels, now significantly above the normal range, indicating increased tumor activity. His anemia has worsened slightly, with a hemoglobin level now at 10.8 g/dL, which correlates with his increased fatigue.

These findings prompt an urgent multidisciplinary team meeting to reassess the treatment strategy. The team considers the possibility of thoracentesis to alleviate the pleural effusion and improve respiratory function. Additionally, the oncologist discusses adjusting the therapeutic regimen, potentially incorporating targeted therapy in combination with the current treatment to address the aggressive nature of the disease. Throughout this process, the healthcare team emphasizes the importance of ongoing symptom management, including optimizing the patient's oxygenation and addressing his anemia to enhance his quality of life as he continues his treatment journey.

Section 3

Following the multidisciplinary team meeting, a decision is made to proceed with thoracentesis to address the patient's right-sided pleural effusion and improve his respiratory symptoms. The procedure is performed successfully, and approximately 800 mL of straw-colored fluid is removed. Post-procedure, the patient reports a noticeable improvement in his breathing, and his oxygen saturation increases to 95% on room air. The pleural fluid is sent for cytological analysis, which later confirms the presence of malignant cells, consistent with metastatic melanoma.

In the meantime, adjustments are made to the patient's treatment regimen. The oncologist introduces a targeted therapy agent, vemurafenib, after genomic profiling of the tumor reveals a BRAF V600E mutation. This mutation-specific therapy is intended to work synergistically with the ongoing immune checkpoint inhibitors to slow tumor progression. The patient is educated on the potential side effects of the new medication, including photosensitivity and joint pain, and is advised to report any new symptoms promptly.

Despite the initial improvement in respiratory function, the patient presents two weeks later with new onset of bilateral lower extremity edema and a mild increase in weight. Vital signs reveal a slightly elevated heart rate of 102 bpm and blood pressure of 150/88 mmHg. Laboratory tests show a serum creatinine level of 1.8 mg/dL, up from 1.2 mg/dL, indicating possible renal involvement. These findings suggest emerging complications, potentially related to his treatment regimen, necessitating further evaluation and possible modification of his therapeutic plan to prevent further renal impairment and manage the edema effectively. The healthcare team continues to monitor his symptoms closely, reinforcing the importance of maintaining open communication and regular follow-up appointments to swiftly address any new developments in his condition.

Section 4

The patient's clinical situation necessitates a thorough evaluation to discern the cause of his new symptoms, primarily focusing on the bilateral lower extremity edema and renal impairment. Upon initial assessment, the healthcare team notes mild pitting edema in both legs, which extends up to the knees, alongside a slightly distended abdomen. The patient's lung sounds remain clear, and there is no evidence of jugular venous distention, which helps to rule out significant heart failure as an immediate cause. However, the elevated heart rate and blood pressure indicate a possible fluid overload or hypertension secondary to renal issues or medication effects.

Further diagnostic investigations, including a comprehensive metabolic panel and urinalysis, are ordered to evaluate renal function and rule out nephrotoxicity. The metabolic panel reveals a further increase in serum creatinine to 2.0 mg/dL, confirming a trend towards deteriorating kidney function. Urinalysis shows mild proteinuria and microscopic hematuria. These findings suggest that the patient may be experiencing drug-induced nephrotoxicity, possibly related to the newly introduced vemurafenib or the cumulative effect of ongoing immunotherapy. The oncologist considers temporarily holding the vemurafenib and consults with a nephrologist to explore nephroprotective strategies.

To address the edema, the healthcare team initiates diuretic therapy with furosemide, carefully monitoring the patient's electrolytes and renal function. The patient is educated on the importance of fluid restriction and low-sodium diet to aid in reducing fluid retention. Regular follow-up appointments are scheduled to ensure close monitoring of his renal parameters and response to interventions. The multidisciplinary team remains vigilant in adjusting the therapeutic approach, understanding that prompt identification and management of these complications are crucial to mitigating further adverse effects and optimizing the patient's overall treatment plan.

Section 5

As the patient continues with diuretic therapy, there is a noticeable reduction in the bilateral lower extremity edema. However, during a routine follow-up appointment, the patient reports experiencing increased fatigue and mild shortness of breath upon exertion. Vital signs reveal a blood pressure of 145/90 mmHg, a heart rate of 98 beats per minute, and an oxygen saturation of 95% on room air. Despite the improvement in edema, a physical examination shows that the abdominal distention has slightly worsened, raising concerns about possible fluid accumulation in the abdominal cavity. The healthcare team performs an abdominal ultrasound, which reveals mild ascites.

Lab work is repeated, showing a serum creatinine level now at 2.2 mg/dL, indicating a continued trend of renal impairment. Additionally, serum electrolytes reveal mild hyponatremia with a sodium level of 132 mEq/L, raising concerns about the consequences of diuretic therapy and fluid management. The urinalysis continues to show proteinuria, and a renal ultrasound is ordered to assess structural changes or obstructions.

The patient's oncologist and nephrologist collaborate to optimize the management plan, considering the potential for vemurafenib to contribute to renal issues. They decide to continue holding vemurafenib while adjusting the diuretic therapy to prevent further electrolyte imbalances. The healthcare team emphasizes monitoring the patient's dietary sodium and fluid intake closely. The patient's care plan involves more frequent monitoring of renal function and electrolyte levels, and a plan is made to reassess the need for vemurafenib based on renal function stabilization. The team remains open to exploring alternative therapies, understanding the delicate balance required to manage the patient's melanoma treatment while protecting renal health.